Natera Inc (NTRA)

$87.28

-3.05

(-3.38%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Natera Inc

  • Increasing Revenue

    Revenue is up for the last 11 quarters, 142.02M → 311.10M (in $), with an average increase of 7.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -142.57M → -78.03M (in $), with an average increase of 17.3% per quarter

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.4% return, outperforming this stock by 20.9%

Performance

  • $87.22
    $90.28
    $87.28
    downward going graph

    0.07%

    Downside

    Day's Volatility :3.39%

    Upside

    3.32%

    downward going graph
  • $36.90
    $98.82
    $87.28
    downward going graph

    57.72%

    Downside

    52 Weeks Volatility :62.66%

    Upside

    11.68%

    downward going graph

Returns

PeriodNatera IncSector (Health Care)Index (Russel 2000)
3 Months
33.7%
-0.7%
0.0%
6 Months
115.69%
6.6%
0.0%
1 Year
79.9%
3.7%
-1.5%
3 Years
-13.91%
14.0%
-21.8%

Highlights

Market Capitalization
10.9B
Book Value
$6.4
Earnings Per Share (EPS)
-3.78
PEG Ratio
0.0
Wall Street Target Price
100.94
Profit Margin
-40.16%
Operating Margin TTM
-27.17%
Return On Assets TTM
-19.67%
Return On Equity TTM
-59.11%
Revenue TTM
1.1B
Revenue Per Share TTM
9.41
Quarterly Revenue Growth YOY
43.2%
Gross Profit TTM
364.0M
EBITDA
-424.5M
Diluted Eps TTM
-3.78
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.32
EPS Estimate Next Year
-1.2
EPS Estimate Current Quarter
-0.73
EPS Estimate Next Quarter
-0.75

Analyst Recommendation

Buy
    85%Buy
    9%Hold
    4%Sell
Based on 21 Wall street analysts offering stock ratings for Natera Inc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
19
Hold
2
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 15.65%

Current $87.28
Target $100.94

Company Financials

FY18Y/Y Change
Revenue
257.7M
↑ 22.15%
Net Income
-128.2M
↓ 5.99%
Net Profit Margin
-49.74%
↑ 14.88%
FY19Y/Y Change
Revenue
302.3M
↑ 17.34%
Net Income
-124.8M
↓ 2.6%
Net Profit Margin
-41.29%
↑ 8.45%
FY20Y/Y Change
Revenue
391.0M
↑ 29.33%
Net Income
-229.7M
↑ 84.05%
Net Profit Margin
-58.76%
↓ 17.47%
FY21Y/Y Change
Revenue
625.5M
↑ 59.97%
Net Income
-471.7M
↑ 105.32%
Net Profit Margin
-75.42%
↓ 16.66%
FY22Y/Y Change
Revenue
820.2M
↑ 31.13%
Net Income
-547.8M
↑ 16.13%
Net Profit Margin
-66.79%
↑ 8.63%
FY23Y/Y Change
Revenue
1.1B
↑ 31.99%
Net Income
-434.8M
↓ 20.63%
Net Profit Margin
-40.16%
↑ 26.63%
Q3 FY22Q/Q Change
Revenue
210.6M
↑ 6.27%
Net Income
-121.5M
↓ 16.31%
Net Profit Margin
-57.67%
↑ 15.56%
Q4 FY22Q/Q Change
Revenue
217.3M
↑ 3.14%
Net Income
-142.6M
↑ 17.36%
Net Profit Margin
-65.63%
↓ 7.96%
Q1 FY23Q/Q Change
Revenue
241.8M
↑ 11.28%
Net Income
-136.9M
↓ 3.95%
Net Profit Margin
-56.64%
↑ 8.99%
Q2 FY23Q/Q Change
Revenue
261.4M
↑ 8.13%
Net Income
-110.8M
↓ 19.08%
Net Profit Margin
-42.39%
↑ 14.25%
Q3 FY23Q/Q Change
Revenue
268.3M
↑ 2.64%
Net Income
-109.0M
↓ 1.6%
Net Profit Margin
-40.64%
↑ 1.75%
Q4 FY23Q/Q Change
Revenue
311.1M
↑ 15.95%
Net Income
-78.0M
↓ 28.43%
Net Profit Margin
-25.08%
↑ 15.56%
FY18Y/Y Change
Total Assets
268.2M
↑ 50.0%
Total Liabilities
236.0M
↑ 24.78%
FY19Y/Y Change
Total Assets
582.7M
↑ 117.27%
Total Liabilities
303.9M
↑ 28.79%
FY20Y/Y Change
Total Assets
932.2M
↑ 59.98%
Total Liabilities
445.9M
↑ 46.71%
FY21Y/Y Change
Total Assets
1.2B
↑ 32.65%
Total Liabilities
583.2M
↑ 30.78%
FY22Y/Y Change
Total Assets
1.4B
↑ 12.78%
Total Liabilities
688.7M
↑ 18.1%
FY23Y/Y Change
Total Assets
1.5B
↑ 4.49%
Total Liabilities
691.8M
↑ 0.45%
Q3 FY22Q/Q Change
Total Assets
1.0B
↓ 5.42%
Total Liabilities
647.5M
↑ 4.03%
Q4 FY22Q/Q Change
Total Assets
1.4B
↑ 38.19%
Total Liabilities
688.7M
↑ 6.37%
Q1 FY23Q/Q Change
Total Assets
1.3B
↓ 5.42%
Total Liabilities
668.3M
↓ 2.97%
Q2 FY23Q/Q Change
Total Assets
1.2B
↓ 5.38%
Total Liabilities
651.7M
↓ 2.48%
Q3 FY23Q/Q Change
Total Assets
1.4B
↑ 15.92%
Total Liabilities
661.9M
↑ 1.55%
Q4 FY23Q/Q Change
Total Assets
1.5B
↑ 0.73%
Total Liabilities
691.8M
↑ 4.52%
FY18Y/Y Change
Operating Cash Flow
-70.6M
↓ 27.08%
Investing Cash Flow
-5.2M
↓ 137.44%
Financing Cash Flow
113.7M
↑ 41.5%
FY19Y/Y Change
Operating Cash Flow
-63.4M
↓ 10.11%
Investing Cash Flow
-266.4M
↑ 5060.88%
Financing Cash Flow
340.8M
↑ 199.65%
FY20Y/Y Change
Operating Cash Flow
-182.5M
↑ 187.67%
Investing Cash Flow
-331.5M
↑ 24.44%
Financing Cash Flow
500.8M
↑ 46.97%
FY21Y/Y Change
Operating Cash Flow
-335.2M
↑ 83.68%
Investing Cash Flow
-205.2M
↓ 38.09%
Financing Cash Flow
576.2M
↑ 15.04%
FY22Y/Y Change
Operating Cash Flow
-431.5M
↑ 28.72%
Investing Cash Flow
330.3M
↓ 260.99%
Financing Cash Flow
482.6M
↓ 16.24%
Q3 FY22Q/Q Change
Operating Cash Flow
-102.2M
↓ 7.76%
Investing Cash Flow
66.6M
↑ 91.44%
Financing Cash Flow
1.4M
↓ 84.38%
Q4 FY22Q/Q Change
Operating Cash Flow
-81.1M
↓ 20.66%
Investing Cash Flow
21.9M
↓ 67.09%
Financing Cash Flow
468.2M
↑ 33508.97%
Q1 FY23Q/Q Change
Operating Cash Flow
-80.9M
↓ 0.29%
Investing Cash Flow
15.7M
↓ 28.59%
Financing Cash Flow
2.3M
↓ 99.51%
Q2 FY23Q/Q Change
Operating Cash Flow
-78.4M
↓ 3.1%
Investing Cash Flow
47.0M
↑ 200.49%
Financing Cash Flow
9.3M
↑ 304.69%

Technicals Summary

Sell

Neutral

Buy

Natera Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Natera Inc
Natera Inc
0.23%
115.69%
79.9%
-13.91%
387.22%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-9.73%
12.44%
-0.8%
-9.52%
118.88%
Agilent Technologies Inc.
Agilent Technologies Inc.
-7.9%
23.88%
-3.2%
0.79%
76.64%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-5.65%
17.12%
-6.43%
12.22%
110.66%
Danaher Corp.
Danaher Corp.
-4.8%
16.89%
-6.54%
-1.07%
88.84%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-10.49%
20.27%
12.09%
5.1%
70.85%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Natera Inc
Natera Inc
NA
NA
0.0
-2.32
-0.59
-0.2
NA
6.4
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.76
48.76
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
33.53
33.53
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.85
35.85
2.81
21.56
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
42.54
42.54
3.13
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.74
31.74
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Natera Inc
Natera Inc
Buy
$10.9B
387.22%
NA
-40.16%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$40.7B
118.88%
48.76
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.1B
76.64%
33.53
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$211.7B
110.66%
35.85
13.99%
Danaher Corp.
Danaher Corp.
Buy
$178.0B
88.84%
42.54
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.1B
70.85%
31.74
9.06%

Institutional Holdings

  • Vanguard Group Inc

    9.09%

  • JPMorgan Chase & Co

    6.59%

  • Fred Alger Management, LLC

    5.86%

  • BlackRock Inc

    5.22%

  • Samlyn Capital, LLC

    3.21%

  • Farallon Capital Management, L.L.C.

    2.88%

Corporate Announcements

  • Natera Inc Earnings

    Natera Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the

Organization
Natera Inc
Employees
3282
CEO
Dr. Matthew Rabinowitz Ph.D.
Industry
Health Technology

Discover More

FAQs